The impact of adjunctive eptifibatide therapy with percutaneous coronary intervention for acute myocardial infarction

References

• Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998;98:734–41.
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, et al. Effect of glycoprotein IIb/ IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915–21.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895–903.
   PubMed Web of Science ®Google Scholar
• Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 2003;42:1879–885.
   PubMed Web of Science ®Google Scholar
• Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, et al. CADILLAC Investigators. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2003;108:1316–23.
   PubMed Web of Science ®Google Scholar
• Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol. 2003;42(11):1886–89.
   Google Scholar
• Collet JP, Montalescot G, Lesty C, Mishal Z, Soria J, Choussat R, et al. Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation. 2001;103:2328–31.
   Google Scholar
• Kaul U, Gupta RK, Haridas KK, Ramesh SS, Sethi KK, Singh B, et al. Integrilin in Acute Myocardial Infarction (INAMI) Stenting Study Investigators. Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study. Catheter Cardiovasc Interv. 2002;57:497–503.
   Google Scholar
• Wong CB. Using eptifibatide in patients undergoing coronary angioplasty with acute myocardial infarction. Catheter Cardiovasc Interv. 2003;60:423–4.
   Google Scholar
• Lee DP, Herity NA, Hiatt BL, Fearon WF, Rezaee M, Carter AJ, et al. Tirofiban Given in the Emergency Room before Primary Angioplasty pilot trial. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes. Circulation. 2003;107:1497–501.
   PubMed Web of Science ®Google Scholar
• Martinez-Rios MA, Rosas M, Gonzalez H, Pena-Duque MA, Martinez-Sanchez C, Gaspar J, et al. SASTRE Investigators. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction. Am J Cardiol. 2004;93:280–7.
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Ricciardi MJ, Ling FS, Carrozza JP Jr, Dua V, Garringer J, et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol. 2003;92:977–80.
   PubMedGoogle Scholar
• O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, et al. ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial). Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA. 2001;285:2468–73.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute STsegment elevation myocardial infarction: a meta-analysis. JAMA. 2004;292:362–6.
   PubMed Web of Science ®Google Scholar
• Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888–94.
   PubMed Web of Science ®Google Scholar
• McCollam PL, Foster DA, Riesmeyer JS. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Health Syst Pharm. 2003;60:1251–6.
   Google Scholar